Non-interventional Safety Study to Investigate Pregnancy Outcomes in Female Patients Exposed to SC Peginterferon Beta-1a and IM Interferon Beta-1a Reported in a German Patient Support Program
Latest Information Update: 20 Apr 2023
Price :
$35 *
At a glance
- Drugs Interferon beta-1a (Primary) ; Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 01 Nov 2021 Status changed from recruiting to completed.
- 06 Aug 2021 Planned End Date changed from 31 Jul 2021 to 15 Oct 2021.
- 06 Aug 2021 Planned primary completion date changed from 31 Jul 2021 to 15 Oct 2021.